Cathie Wood's $21 Million Tuesday Move: Peter Thiel's Crypto Play Gets Boost In Ark Portfolio - Grayscale Bitcoin Mini Trust ( BTC ) Common units of fractional undivided beneficial interest ( ARCA:BTC )
Cathie Wood-led Ark Invest made significant trades on Tuesday with notable activity in Bullish BLSH, Robinhood Markets Inc. HOOD, and Tempus AI Inc. TEM. ArrivedBuy shares of homes and vacation rentals for as little as $100. Get Started
Investors Heavily Search CRISPR Therapeutics AG ( CRSP ) : Here is What You Need to Know
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Cathie Wood's 'Apocalypse Squad' Play? Ark Scoops Up $14.2 Million Worth Of Robinhood Stock - ARK Autonomous Technology & Robotics ETF ( BATS:ARKQ ) , ARK Innovation ETF ( BATS:ARKK )
Ark Invest, led by Cathie Wood, executed notable trades on Monday, focusing on Robinhood Markets Inc. HOOD and Deere & Co. DE. ArrivedBuy shares of homes and vacation rentals for as little as $100. Get Started Interactive BrokersTrade global markets with low costs and pro-level tools at ...
Cathie Wood Bets $19 Million More On Jack Dorsey's Block Amid Bitcoin's All-Time High Push, Dumps Shopify Stock - ARK Fintech Innovation ETF ( BATS:ARKF )
On Monday, Cathie Wood-led Ark Invest made significant trades involving Block Inc. XYZ and Shopify Inc. SHOP.
Here is What to Know Beyond Why CRISPR Therapeutics AG ( CRSP ) is a Trending Stock
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Cathie Wood's Ark Dumps Block Stock Worth $4.8 Million As Bitcoin-Heavy Company Preps Q2 Results - ARK Innovation ETF ( BATS:ARKK )
Cathie Wood-led Ark Invest executed a significant trade in Block Inc. XYZ on Tuesday. The move comes just days before the company's much-anticipated second-quarter earnings, due on Thursday, and following its high-profile addition to the S&P 500.
CRSP Stock Down on Huge Q2 Loss, Focus on Increasing Casgevy Adoption
CRISPR Therapeutics posts a wider second-quarter loss tied to Sirius deal costs, while Casgevy adoption gains momentum across global markets.
Cathie Wood Drops $8.3 Million On AMD And Nvidia In Monday Trading Blitz, Sells Robinhood Stock Amid 'Project Crypto' Buzz - ARK Fintech Innovation ETF ( BATS:ARKF ) , Advanced Micro Devices ( NASDAQ:AMD )
On Monday, Cathie Wood-led Ark Invest made significant trades involving Advanced Micro Devices Inc. AMD, NVIDIA Corp NVDA, and Robinhood Markets Inc HOOD. These trades highlight Ark's strategic positioning in the tech and financial sectors. ArrivedBuy shares of homes and vacation rentals for as ...
CRISPR Therapeutics AG ( CRSP ) Reports Q2 Loss, Lags Revenue Estimates
CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of +12.24% and -86.45%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
-CASGEVY® momentum building. >75 authorized treatment centers ( ATCs ) activated globally, achieving the target goal and ~115 patients have had cells collected across all regions. positioning the program for strong future ...
New Strong Sell Stocks for August 1st
CRSP, CSTL and SIGI have been added to the Zacks Rank #5 (Strong Sell) List on August 1, 2025.
CRISPR Therapeutics AG ( CRSP ) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $56.26, indicating a -2.46% shift from the previous trading day.
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
CRISPR-based innovators like NTLA, EDIT and PRME are gaining traction as genomics reshapes the future of medicine and biotech ...
Should You Invest in CRISPR Therapeutics ( CRSP ) Based on Bullish Wall Street Views?
According to the average brokerage recommendation (ABR), one should invest in CRISPR Therapeutics (CRSP). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Will Beam Therapeutics Inc. ( BEAM ) Report Negative Q2 Earnings? What You Should Know
Beam Therapeutics (BEAM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for July 29th
BUR, CRSP and CNL have been added to the Zacks Rank #5 (Strong Sell) List on July 29, 2025.
Cathie Wood Goes On A $20M Bitmine Immersion Bargain Hunt As Ark Trims Robinhood And Palantir Stakes - ARK Fintech Innovation ETF ( BATS:ARKF )
On Monday, Cathie Wood-led Ark Invest made significant trades, including a notable purchase of Bitmine Immersion Technologies Inc. ( BMNR ) shares. The investment firm also increased its holdings in Alphabet Inc. GOOG and NVIDIA Corp NVDA, while reducing its stake in Robinhood Markets Inc.
CRISPR Therapeutics to Report Q2 Earnings: What's in the Cards?
CRSP investors await the company's Q2 results with a focus on Casgevy sales growth and updates on gene-editing pipeline progress.
CRISPR Therapeutics AG ( CRSP ) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
CRISPR Therapeutics (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CRISPR Therapeutics AG ( CRSP ) Stock Falls Amid Market Uptick: What Investors Need to Know
CRISPR Therapeutics AG (CRSP) concluded the recent trading session at $64.76, signifying a -1.97% move from its prior day's close.
CRISPR Therapeutics AG ( CRSP ) Stock Slides as Market Rises: Facts to Know Before You Trade
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $66.06, moving 3.05% from the previous trading session.
[Latest] Global CRISPR Gene Editing Market Size/Share Worth USD 12.6 Billion by 2034 at a 13.01% CAGR: Custom Market Insights ( Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis )
Austin, TX, USA, July 25, 2025 ( GLOBE NEWSWIRE ) -- Custom Market Insights has published a new research report titled "CRISPR Gene Editing Market Size, Trends and Insights By Product ( Kits and Reagents, Services ) , By Gene Editing Modality ( Ex-Vivo Editing, In-Vivo Editing ) , By Technology ...
CRISPR Therapeutics AG ( CRSP ) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Independent Bank Posts Upbeat Earnings, Joins Blaize Holdings, Interactive Brokers Group And Other Big Stocks Moving Higher On Friday - Applied Digital ( NASDAQ:APLD )
U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday. Shares of Independent Bank Corp. INDB rose sharply during Friday's session after the company reported second-quarter financial results and beat its adjusted EPS and revenue estimates.
CRISPR Therapeutics AG ( CRSP ) Declines More Than Market: Some Information for Investors
In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $52.73, denoting a -6.54% move from the preceding trading day.
Is It Worth Investing in CRISPR Therapeutics ( CRSP ) Based on Wall Street's Bullish Views?
The average brokerage recommendation (ABR) for CRISPR Therapeutics (CRSP) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
CRISPR Therapeutics AG ( CRSP ) Is a Trending Stock: Facts to Know Before Betting on It
CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
CRISPR Stock Surges in Recent Weeks: What's Going On? - CRISPR Therapeutics ( NASDAQ:CRSP )
CRISPR reports early data for CTX310, showing major drops in triglycerides and LDL. Analysts maintain mixed ratings on the stock, with price targets ranging from $30 to $120. Get daily-updated rankings across momentum, growth, value, trends, and quality to spot the strongest stocks in any market.
CRISPR Therapeutics ( CRSP ) Moves 9.6% Higher: Will This Strength Last?
CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Innovation ETF ( ARKK ) Hits New 52-Week High
Cathie Wood's ARKK hits a 52-week high after bold biotech moves, signaling renewed momentum in disruptive tech.
Here's Why CRISPR Therapeutics AG ( CRSP ) Fell More Than Broader Market
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $51.19, representing a -1.88% change from its previous close.
CRISPR Therapeutics AG ( CRSP ) is Attracting Investor Attention: Here is What You Should Know
CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Is CRISPR Therapeutics ( CRSP ) a Buy as Wall Street Analysts Look Optimistic?
Based on the average brokerage recommendation (ABR), CRISPR Therapeutics (CRSP) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
3 Promising Genomics Stocks to Keep an Eye On in 2025
Investors interested in the Genomics and Synthetic Biology theme should keep an eye on MGTX, BEAM and KRYS.
CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline
-New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides ( TG ) and low-density lipoprotein ( LDL ) , with peak reduction of up to 82% in TG and up to 86% in LDL, with a well-tolerated safety ...
Cathie Wood Doubles Down On Shopify, Buys The Dip - Dumps $4.6 Million Worth Of Robinhood Stock At Peak - ARK Fintech Innovation ETF ( BATS:ARKF ) , ARK Innovation ETF ( BATS:ARKK )
Cathie Wood-led Ark Invest made notable trades on Wednesday, focusing on Shopify Inc. SHOP and Robinhood Markets Inc. HOOD.
CRISPR Therapeutics AG ( CRSP ) Stock Moves 1.88%: What You Should Know
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $47.66, moving +1.88% from the previous trading session.
CRISPR Therapeutics AG ( CRSP ) Surpasses Market Returns: Some Facts Worth Knowing
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $46.78, marking a +2.7% move from the previous day.
CRISPR Therapeutics AG ( CRSP ) Increases Despite Market Slip: Here's What You Need to Know
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $44.43, representing a +2.87% change from its previous close.
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst - Eli Lilly ( NYSE:LLY ) , Verve Therapeutics ( NASDAQ:VERV )
Eli Lilly offered a 115% premium for Verve, signaling a major vote of confidence in gene editing platforms. HC Wainwright and William Blair downgraded Verve after the deal. Last Chance: See the "Power Pattern" That Delivered Winners 9 Out of the Last 10 Summers. Get The Details Here
CRISPR Therapeutics AG ( CRSP ) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
CRISPR Therapeutics AG ( CRSP ) Rises Higher Than Market: Key Facts
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $42.94, representing a +2.02% change from its previous close.
Cathie Wood Just Flagged The Start Of A Biotech Revolution: These 2 Stocks With 10x Potential Are Leading It - ARK Genomic Revolution ETF ( BATS:ARKG ) , ARK Innovation ETF ( BATS:ARKK )
ARK Invest founder Cathie Wood is betting big on a new frontier in biotechnology, one she says could unlock massive market opportunity, and two companies are already leading the way, with the potential to grow 10x from their current levels.
Investors Heavily Search CRISPR Therapeutics AG ( CRSP ) : Here is What You Need to Know
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
CRISPR Therapeutics ( CRSP ) Up 11.1% Since Last Earnings Report: Can It Continue?
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cathie Wood Dumps $9.9M Tesla Despite Musk's '24/7' Pledge, Loads Up on Nvidia Before Earnings - Advanced Micro Devices ( NASDAQ:AMD ) , ARK Innovation ETF ( BATS:ARKK )
On Tuesday, Cathie Wood-led Ark Invest executed notable trades involving NVIDIA Corp NVDA, Advanced Micro Devices Inc. AMD, and Tesla Inc. TSLA. These trades come amid significant market developments and strategic shifts, capturing the attention of investors and analysts alike.
CRISPR Therapeutics AG ( CRSP ) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
3 Top Genomics Stocks to Add to Your Portfolio in 2025
Investors interested in the Genomics and Synthetic Biology theme may consider adding these three stocks to their portfolio - Intellia Therapeutics (NTLA), uniQure (QURE) and Verve Therapeutics (VERV).
CRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA Therapies
-Collaboration brings together complementary capabilities to co-develop and co-commercialize SRSD107, a next generation, long-acting Factor XI ( FXI ) small interfering RNA ( siRNA ) for the treatment of thromboembolic ...
CRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA Therapies - CRISPR Therapeutics ( NASDAQ:CRSP )
-Collaboration brings together complementary capabilities to co-develop and co-commercialize SRSD107, a next generation, long-acting Factor XI ( FXI ) small interfering RNA ( siRNA ) for the treatment of thromboembolic disorders-
